Low desire and arousal changes are common, medical, and treatable—yet women are still told to just live with them. We disagree.
Because 'it's normal, live with it' is not a treatment plan.
Hypoactive sexual desire disorder is one of the most common sexual health concerns women face—and it's treatable.
You're not alone
The peptide behind Vyleesi®, FDA-approved for low desire in premenopausal women.
Medications, stress, sleep, and hormonal context all get considered—not just a prescription reflex.
Secure intake, encrypted messaging, and plain packaging at every step.
Most women wait years before raising desire concerns with anyone. From here, it's a private intake, a provider who listens, and options that have actual evidence behind them.
Get Started
“HDMeds has been a game changer. The process was simple, the care is incredible, and I've lost over 32 lbs in 4 months. I finally feel like myself again!”
“HDMeds helped me optimize my health and energy. I feel better than I have in years.”
“After a few weeks, my skin looks brighter and my hair feels stronger. I love that my plan is personalized and shipped discreetly to my door.”
“HDMeds made it easy to get the help I needed. Professional, discreet, and effective.”
“HDMeds has been a game changer. The process was simple, the care is incredible, and I've lost over 32 lbs in 4 months. I finally feel like myself again!”
“HDMeds helped me optimize my health and energy. I feel better than I have in years.”
“After a few weeks, my skin looks brighter and my hair feels stronger. I love that my plan is personalized and shipped discreetly to my door.”
“HDMeds made it easy to get the help I needed. Professional, discreet, and effective.”
Extremely—low sexual desire is one of the most commonly reported sexual health concerns among women, across every life stage. When it's persistent and distressing, it has a clinical name (HSDD) and real treatment options.
Options include PT-141 (bremelanotide)—FDA-approved as Vyleesi® for premenopausal women with HSDD—alongside addressing contributors like medications, stress, sleep, and hormonal changes. Your provider builds the plan around your situation.
PT-141 activates melanocortin receptors in the brain's desire pathways and is used as-needed before intimacy, rather than daily. Your provider will explain timing, dosing, and what to expect.
No insurance needed—HDMeds uses transparent cash pricing. Your evaluation, messaging, and shipments stay completely private.
Whenever it bothers you—that's the clinical threshold that matters. Sudden changes alongside other symptoms are also worth raising, and your provider will flag anything that deserves in-person follow-up.
Private, provider-led care for low desire and arousal—built around you.
